News of Note—Lonza adds API lines for AstraZeneca; Biocon gets EU OK

stock market prices
(Pixabay)

> Lonza is adding two lines at its site in Visp, Switzerland, for production of highly potent APIs as part of a supply deal with AstraZeneca. Release

> Indian biosimilar maker Biocon says its biologics drug product facility and its drug substance facility in Bengaluru were approved by the European Medicines Agency following a March inspection. Release

> AptarGroup in Crystal Lake, Illinois, is spending about $50 million to buy pharmaceutical services companies Nanopharm and Gateway Analytical to expand its offerings to the biopharma industry. Release

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

> The Medicines and Healthcare products Regulatory Agency in the U.K. is recalling two batches of 500 mg paracetamol tablets produced by M&A Pharmachem because of discoloration caused by fungi. Stor

Suggested Articles

The FDA lambasted Strides Pharma in a warning letter after inspectors found testing records in the trash and in bags by a shredder.

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.

Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.